A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
(CALIBRATE-HF)
- Registry ID
- 2025-525033-31-00
- Source registry
- CTIS
- Status
- Authorised
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- Cardurion Pharmaceuticals Inc.
- Enrollment
- 102
- Last update
- 2026-08-14
Conditions
- Diseases [C] - Cardiovascular Diseases [C14]
- heart failure
Primary outcomes
Composite Z-score calculated as the average of Z-scores for the change from baseline at 24 weeks for the following 6 endpoints: NT-proBNP (log-transformed), Left ventricular end-diastolic volume index (LVEDVI), Left ventricular end-systolic volume index (LVESVI), E/e′ ratio, Global longitudinal strain (GLS), Left atrial volume index (LAVI).
Locations
- , , Slovakia
- , , Latvia
- , , Italy
Related clinical trials
- RECOMPENSE: Right vEntricular COMPENsation with SotatercEpt. A prospective single arm open label phase IV study to evaluate the effects of sotatercept on right ventricular function in pulmonary arterial hypertension
- Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events
- CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
- Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension
- Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation -
The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial
View on source registry